

# Phenotypic and genotypic correlation of carbapenemase-producing Enterobacteriaceae and problems experienced in routine screening

A Singh-Moodley,<sup>1,2</sup> BSc, BMedSc Hons, MMedSc, PhD; O Perovic,<sup>1,2</sup> MD, DTM&H, FC Path (SA) (Microbiol), MMed (Microbiol)

<sup>1</sup> Centre for Healthcare-associated infections, Antimicrobial Resistance and Mycoses, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa

<sup>2</sup> Department of Clinical Microbiology and Infectious Diseases, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Corresponding author: A Singh-Moodley (ashikas@nicd.ac.za)

**Background.** The emergence and transmission of carbapenem-resistant Enterobacteriaceae (CRE) is a concern in both the clinical and public health arenas. Reliable and accurate detection of these organisms is required for patient management and infection prevention and control purposes. In the routine laboratory, phenotypic methods are utilised for identification of CRE.

**Objectives.** To investigate the phenotypic profiles of suspected carbapenemase-producing Enterobacteriaceae (CPE) isolates generated by the automated MicroScan Walkaway system making use of the Clinical and Laboratory Standards Institute (CLSI) guidelines, and correlate these with carbapenemase production by molecular methods.

**Methods.** Antimicrobial susceptibility testing was performed using the MicroScan Walkaway system, and the presence of six carbapenemase genes (*bla*<sub>NDM</sub>, *bla*<sub>VIM</sub>, *bla*<sub>IMP</sub>, *bla*<sub>OXA-48</sub> and variants, *bla*<sub>GES</sub> and *bla*<sub>KPC</sub>) was screened for using a multiplex real-time polymerase chain reaction.

**Results.** A total of 2 678 isolates were evaluated. *Klebsiella pneumoniae* accounted for 62.9% of the isolates (*n*=1 685), followed by *Enterobacter cloacae* (*n*=361, 13.5%). Carbapenemases accounted for 75.2% of isolates; *bla*<sub>OXA-48</sub> and its variants predominated (*n*=978, 36.5%), followed by *bla*<sub>NDM</sub> (*n*=904, 33.8%), *bla*<sub>VIM</sub> (*n*=108, 4.0%), *bla*<sub>IMP</sub> (*n*=35, 1.3%), *bla*<sub>GES</sub> (*n*=24, 0.9%) and *bla*<sub>KPC</sub> (*n*=18, 0.7 %).

**Conclusions.** A considerable number of isolates expressing a carbapenemase or carbapenemases (the majority of which were *bla*<sub>OXA-48</sub> producing) were susceptible to third- and fourth-generation cephalosporins and carbapenems, demonstrating that confirmed carbapenemase-producing isolates are not presenting as possible carriers of carbapenemases using routine diagnostic methods. Similar results were obtained when CLSI and European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints were applied and are suitable for the purpose of patient management. However, since genotyping assays are costly, it is suggested that routine laboratories first perform comprehensive phenotypic screening for CPE.

*S Afr Med J* 2018;108(6):495-501. DOI:10.7196/SAMJ.2018.v108i6.12878

Multidrug-resistant organisms are a global clinical and public health concern.<sup>[1,2]</sup> There is an increase in the detection of Enterobacteriaceae strains with resistance observed against beta-lactams, fluoroquinolones, aminoglycosides and polymyxins.<sup>[3]</sup> Resistance mechanisms to the beta-lactams are multifaceted and include outer-membrane permeability changes, upregulation of efflux pumps, the production of an inducible ampicillin class C (AmpC) beta-lactamase, and enzymes that hydrolyse the antimicrobial agent. Beta-lactamases are enzymes that include the cephalosporinases, such as the extended-spectrum beta-lactamases (ESBLs) and the carbapenemases, namely the metallo-beta-lactamases (MBLs), which consist of New Delhi MBLs (NDMs), IMPs (imipenemases) and VIMs (Verona integron-encoded MBLs), the *Klebsiella pneumoniae* carbapenemases (KPCs) and the oxacillinases such as OXA-48.<sup>[3]</sup>

It is important to note the difference between carbapenem-resistant Enterobacteriaceae (CRE) and carbapenemase-producing Enterobacteriaceae (CPE). CRE are resistant to carbapenems due to carbapenemase production or via combinations of AmpC, ESBLs and impermeability. These multiple resistance mechanisms may play a role in acquiring or expressing carbapenem resistance. CPE include only those Enterobacteriaceae with a confirmed carbapenemase-producing gene.<sup>[4]</sup> These genes code for the enzymes, carbapenemases,

which are beta-lactamases that hydrolyse almost all beta-lactams including the carbapenems. These enzymes have been classified into Ambler classes A, B and D based on their amino acid sequences.<sup>[3,5]</sup> Class A carbapenemases include KPC and Guiana extended-spectrum beta-lactamase (GES), class B carbapenemases include MBLs, such as VIMs, NDMs and IMPs, and class D consists of OXA-48 and its derivatives.<sup>[6,7]</sup> Carbapenemases were initially chromosomally mediated (mutation within the bacterial chromosome) resulting in resistance in a few specific species, but the majority are now plasmid mediated,<sup>[8,9]</sup> resulting in horizontal transmission among various bacterial species and genera, i.e. transfer from one organism to another. As plasmids are mobile genetic elements (DNA that move around within the genome), their ability to acquire, harbour and disseminate multiple resistance genes contributes to the successful and aggressive transmission of resistant organisms.<sup>[10]</sup>

It is important to prevent the spread of these organisms. However, there are some obstacles, as clinical laboratories do not routinely test for CRE resistance mechanisms and are not able to differentiate between CRE and CPE.<sup>[11]</sup> Clinical routine laboratories make use of phenotypic methods that involve identification of the organism and antimicrobial susceptibility testing (AST). This provides the clinician with information on the organism causing the infection and the

antibiotics to which it is susceptible or resistant, but not the actual mechanism causing the resistance. Molecular methods (also known as genotypic methods) provide this additional information, as they identify the specific resistance genes. Another obstacle in detecting these organisms has been emphasised by studies showing that CPE can be classified as phenotypically susceptible, making their identification all the more challenging,<sup>[12,13]</sup> as carbapenem minimal inhibitory concentrations (MICs) for CPE may be below the clinical breakpoints, which are discriminatory antimicrobial concentrations used in the interpretation of results for susceptibility testing to define isolates as susceptible, intermediate or resistant.<sup>[14]</sup> This means that although a carbapenemase-producing gene may be present, phenotypic AST results display no resistance because routinely used automated AST systems cannot identify very low MICs. It is suggested that because the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints are higher than those recommended by the Clinical and Laboratory Standards Institute (CLSI), some CPE that are susceptible are taken into consideration.<sup>[15-18]</sup> Currently, automated systems are not able to detect all types of carbapenemase producers reliably,<sup>[17]</sup> particularly those exhibiting low MICs, as lower MIC dilutions are not included in the methodology of these systems. This highlights the need to understand the prevalence of these organisms in our current setting and to establish a guide that would be useful for identification of the organisms for clinical management and public health and infection prevention and control purposes.

## Objectives

We evaluated 2 678 Enterobacteriaceae isolates and correlated their phenotypic and genotypic profiles, with the objective of making recommendations for the identification and detection of CPE for both patient management and epidemiological and infection prevention and control purposes.

## Methods

Organism identification and AST were performed using automated systems (VITEK II (bioMérieux, France) and/or the Microflex MALDI-ToF (Bruker Daltonik GmbH, Germany) and the MicroScan Walkaway system (Siemens, USA)). The interpretation of susceptibility was done according to the CLSI guidelines<sup>[19]</sup> and the EUCAST guidelines.<sup>[20]</sup> DNA was extracted using a crude boiling method at 95°C for 25 minutes for cell lysis. The supernatant was harvested and screened for *bla*<sub>NDM</sub>, *bla*<sub>KPC</sub>, *bla*<sub>OXA-48</sub> and its variants (OXA-162, 163, 244, 245, 247, 181, 204, 232), *bla*<sub>GES</sub> (GES-1-9, 11), *bla*<sub>IMP</sub> (IMP-9, 16, 18, 22, 25) and *bla*<sub>VIM</sub> (VIM-1-36) using a multiplex real-time polymerase chain reaction (LightCycler 480 II, Roche Diagnostics, USA), the LightCycler 480 Probes Master kit (Roche Diagnostics, USA) and the individual LightMix Modular kits (Roche Diagnostics, USA).

## Ethical approval

Permission to conduct this study was obtained from the Human Research Ethics Committee (Medical) R14/49, University of the Witwatersrand, Johannesburg, South Africa (SA) (ref. no. M10464). General ethics approval was obtained for routine diagnostic testing, and patient consent was not required. No personal individual information was used.

## Results

A total of 2 678 isolates were evaluated. Isolates were received as part of a referral diagnostic programme and processed in real time. A breakdown of the organisms isolated and specimen types is seen in Table 1. A total of 2 014 isolates (75.2%) harboured one

or a combination of carbapenemases. *bla*<sub>OXA-48</sub> and its variants predominated (*n*=978, 36.5%) followed by *bla*<sub>NDM</sub> (*n*=904, 33.8%), *bla*<sub>VIM</sub> (*n*=108, 4.0%), *bla*<sub>IMP</sub> (*n*=35, 1.3%), *bla*<sub>GES</sub> (*n*=24, 0.9%) and *bla*<sub>KPC</sub> (*n*=18, 0.7%). The majority of the carbapenemase-producing isolates were *Klebsiella* spp. (*n*=1 459, 54.5%), driven predominantly by *K. pneumoniae* (*n*=1 413, 52.8%), followed by *Enterobacter* spp. (*n*=212, 7.9%) with *E. cloacae* (*n*=170, 6.3%) being the predominant species (Fig. 1). Tables 2 and 3 show the MIC breakpoint values for the cephalosporins and carbapenems. As observed in these tables, a considerable number of isolates expressing a carbapenemase or carbapenemases were susceptible to third- and fourth-generation cephalosporins and the carbapenem group of antimicrobial agents when the CLSI<sup>[19]</sup> and EUCAST<sup>[20]</sup> guideline clinical breakpoints were applied, thus indicating the number of isolates that would have been missed using the respective guidelines. There was no difference in the percentage of susceptible isolates expressing a carbapenemase or carbapenemases for cefotaxime, ertapenem, meropenem and doripenem when analysed using both guideline clinical breakpoints. Differences were seen with ceftazidime, which showed a 2% increase in the number of susceptible isolates expressing a carbapenemase

**Table 1. Distribution of organism and specimen type (N=2 678)**

	<i>n</i> (%)
Organism type	
<i>Escherichia coli</i>	178 (6.6)
<i>Serratia marcescens</i>	146 (5.5)
<i>Morganella morganii</i>	28 (1.0)
<i>Enterobacter aerogenes</i>	27 (1.0)
<i>E. asburiae</i>	12 (0.4)
<i>E. cancerogenus</i>	1 (0.0)
<i>E. cloacae</i>	416 (15.5)
<i>E. gergoviae</i>	1 (0.0)
<i>E. kobei</i>	8 (0.3)
<i>Enterobacter</i> spp.	3 (0.1)
<i>Klebsiella pneumoniae</i>	1 685 (62.9)
<i>K. oxytoca</i>	30 (1.1)
<i>Klebsiella</i> spp.	18 (0.7)
<i>Providencia</i> spp.	46 (1.7)
<i>Raoultella</i> spp.	3 (0.1)
<i>Proteus</i> spp.	11 (0.4)
<i>Citrobacter freundii</i>	58 (2.2)
<i>Citrobacter</i> spp.	7 (0.3)
Specimen type	
Unknown	525 (19.6)
Blood	398 (14.9)
Body fluids	142 (5.3)
Bone marrow biopsy	1 (0.0)
Catheter tip vascular	128 (4.8)
Cerebrospinal fluid	10 (0.4)
Drain	3 (0.1)
Lower respiratory tract aspirate	82 (3.1)
Sputum	91 (3.4)
Sterile site aspirate	14 (0.5)
Stool	18 (0.7)
Swabs	539 (20.1)
Tissue	55 (2.1)
Upper respiratory tract swab	16 (0.6)
Urinary catheter	34 (1.3)
Urine	622 (23.2)




Fig. 1. Distribution of organism and carbapenemase types.

*Proteus spp.*: OXA-48, n=4; NDM, n=1

*Raoultella spp.*: NDMs, n=2; VIM, n=1

*Morganella morganii*: OXA-48, n=1; NDMs, n=1

*Providencia spp.*: OXA-48, n=2; NDMs, n=42; VIM, n=1; IMPs, n=2

*Citrobacter spp.*: OXA-48, n=14; NDMs, n=43; GES, n=1; KPCs, n=4

*Serratia marcescens*: OXA-48, n=34; NDMs, n=85; VIM, n=1; GESs, n=4

*Escherichia coli*: OXA-48, n=117; NDMs, n=25; VIM, n=1

*Enterobacter spp.*: OXA-48, n=94; NDMs, n=72; VIMs, n=12; GESs, n=31; KPCs, n=3

*Klebsiella spp.*: OXA-48, n=712; NDMs, n=623; VIMs, n=92; IMPs, n=2; GESs, n=19; KPCs, n=11

(MBLs = metallo-beta-lactamases; NDMs = New Delhi MBLs; VIMs = Verona integron-encoded MBLs; IMPs = imipenemases; GESs = Guiana extended-spectrum beta-lactamases; KPCs = *Klebsiella pneumoniae* carbapenemases.)

or carbapenemases using EUCAST clinical breakpoints, cefepime, which showed a 1% decrease, and imipenem, which showed a 4% decrease. From these data it is further observed that although all six genes were present in the clinically susceptible isolates, the majority of these isolates were *bla*<sub>OXA-48</sub> producing.

## Discussion

This study demonstrates the problems experienced in the detection of CPE. Overall 75.2% of the isolates harboured at least one or a combination of carbapenemase-producing genes, although a substantial number of isolates were phenotypically susceptible. The most predominant carbapenemase type was *bla*<sub>OXA-48</sub> and its variants (n=978, 36.5%), followed by *bla*<sub>NDM</sub> (n=904, 33.8%), *bla*<sub>VIM</sub> (n=108, 4.0%), *bla*<sub>IMP</sub> (n=35, 1.3%), *bla*<sub>GES</sub> (n=24, 0.9%) and *bla*<sub>KPC</sub> (n=18, 0.7%). Limitations of the genotypic method employed should be noted; false-negative results may have occurred because genes were not detected owing to the presence of rare carbapenemase types and/or genetic variants that were not included in the screening assay, namely IMI, SPM, SIM, etc., suggesting that variants and other carbapenemases may potentially have been missed and that the actual proportion of CPE in our study population could have been higher. This is concerning, as the rate of CPE is increasing as demonstrated by the

number of SA studies reporting occurrences and outbreaks.<sup>[13,21-25]</sup>

The majority of the carbapenemase-producing isolates were *K. pneumoniae* (n=1413, 52.8%), followed by *E. cloacae* (n=170, 6.3%). Carbapenem resistance is particularly worrying in intrinsically colistin-resistant organisms such as *Serratia marcescens*, *Providencia* spp. and *Morganella morganii*, which harboured carbapenemases in 124 (4.6%), 47 (1.8%) and 12 (0.5%) isolates, respectively, and accounted for 6.3% of all isolates. Treatment options for patients infected with these isolates are limited, with most conventional treatment options being exhausted.

A considerable number of isolates producing a phenotypically susceptible profile to the third- and fourth-generation cephalosporins and carbapenems expressed carbapenemases. The numbers varied per antimicrobial agent (Tables 2 and 3), but were relatively high. Difficulties in identifying metallo-beta-carbapenemase-producing organisms primarily based on MIC results have been reported previously.<sup>[12]</sup> The most striking carbapenemase type in our study was OXA-48 and its variants. This is not surprising, as this genotype has an atypical hydrolysis profile and clinical isolates harbouring this gene rarely show the resistance phenotype that is attributable to the expression of carbapenemases alone, often expressing other beta-lactamases such as the

ESBLs, resulting in an extensive resistance profile.<sup>[17]</sup> However, intermediate resistance and susceptibility to carbapenems have been observed in various carbapenemase type-producing Enterobacteriaceae, particularly OXA-48/OXA181-producing isolates that do not co-produce an ESBL. Therefore, any Enterobacteriaceae isolate with a decreased carbapenem susceptibility may potentially be considered for screening.<sup>[17]</sup> Furthermore, a study of OXA-48-producer-infected mice has shown that ertapenem and imipenem failed to cure the rodents, even though the MIC values were low.<sup>[26]</sup> This is concerning, as OXA-48 was the predominant genotype in our sample population, indicating that isolates are not presenting as possible carriers of carbapenemases using routine diagnostic methods. A previous report in Enterobacteriaceae with reduced susceptibility to at least one carbapenem has shown that increased resistance to temocillin (MIC >64 mg/mL) and piperacillin-tazobactam may assist in identifying possible OXA-48 producers.<sup>[27]</sup> Other phenotypic tests include the modified Hodge test (MHT), which is able to detect carbapenemase producers and works well for the detection of KPCs and OXA-48 but is less sensitive to NDM producers.<sup>[17]</sup> However, it is improved if zinc is included in the culture medium.<sup>[28]</sup> The MHT often lacks specificity, particularly in the presence of high-level AmpC- or cefotaxime-type ESBL producers, and it is time-consuming, requiring 24 - 48 hours.<sup>[17]</sup> Inhibition of ethylenediaminetetra-acetic acid (EDTA) may be used for identifying MBLs, e.g. the Etest MBL strip (bioMérieux, UK). Imipenem and imipenem/EDTA are efficient for this purpose, particularly if the MBL producers exhibit high-level resistance, but may be problematic for low-level MBL producers. Other inhibitors include boronic acid, specific for KPC detection in *K. pneumoniae* when performed with imipenem or meropenem. These phenotypic tests may be efficient in detecting some carbapenemases, but false-positive results can be obtained, particularly in AmpC producers.<sup>[17]</sup> It is therefore necessary to define an appropriate screening phenotypic method that is both reliable and accurate.

In a previous study, we showed the MicroScan Walkaway system coupled with the CLSI MIC breakpoint ranges as a method of carbapenemase production to have a high sensitivity (98%) and a low specificity (13%) using ertapenem.<sup>[29]</sup> From our results in the present study, using CLSI MIC breakpoint ranges for ertapenem, 157 (57.3%) (Table 2) carbapenemase-producing isolates were not detected as carbapenemase

**Table 2. MIC breakpoint values for the cephalosporins and carbapenems and CLSI guideline clinical breakpoint<sup>[19]</sup> interpretation**

Antimicrobial agent	MIC (mg/mL)	OXA-48 and						Total
		NDMs	variants	VIMs	GESs	IMPs	KPCs	
Cefotaxime	≤1	7	148	2	-	-	-	209
	2	-	9	-	-	-	-	15
	4	-	16	-	1	1	-	21
	8	1	9	1	-	-	-	13
	16	4	10	-	-	-	-	23
	32	11	18	3	2	1	-	45
	>32	881	768	102	21	33	18	2 352
Ceftazidime	≤1	7	162	2	-	1	-	227
	2	-	11	-	1	-	-	17
	4	2	7	-	1	-	-	17
	8	-	19	-	1	-	-	29
	16	3	88	2	2	-	-	117
	>16	892	691	104	19	34	18	2 271
Cefepime	≤1	8	168	2	1	1	-	260
	2	2	20	1	-	-	-	32
	4	4	14	-	-	2	-	41
	8	12	21	2	2	4	-	65
	16	16	60	9	2	5	-	106
	>16	862	695	94	19	23	18	2 174
	Ertapenem	≤0.5	13	128	12	3	1	-
1		11	195	21	-	3	-	324
>1		727	608	57	13	6	10	1 721
2		-	8	4	-	7	-	39
4		4	20	10	1	9	2	56
>4		149	19	4	7	9	6	264
Imipenem	≤1	35	634	8	2	8	1	1 050
	≤2	40	157	14	4	20	1	429
	4	70	40	58	2	2	3	201
	8	274	45	15	2	1	5	356
	>8	485	102	13	14	4	8	642
Meropenem	≤1	34	659	27	3	27	1	1 150
	2	18	77	15	1	1	-	169
	4	49	60	21	1	2	-	216
	8	82	38	27	1	2	4	205
	>8	721	144	18	18	3	13	938
Doripenem	Not tested: not included in panel	155	52	24	9	26	8	428
	≤1	29	669	16	2	8	1	1 072
	2	28	56	14	-	-	-	155
	4	49	54	12	1	1	2	164
	>4	643	147	42	12	-	7	859

MIC = minimal inhibitory concentration; CLSI = Clinical and Laboratory Standards Institute; MBLs = metallo-beta-lactamases; NDMs = New Delhi MBLs; VIMs = Verona integron-encoded MBLs; GESs = Guiana extended-spectrum beta-lactamases; IMPs = imipenemases; KPCs = *Klebsiella pneumoniae* carbapenemases. The white fields indicate the susceptible MIC breakpoint values according to CLSI breakpoints and the number of carbapenemase-producing isolates that would have been missed. CLSI breakpoints: cefepime: ≤2 = susceptible, 4 - 8 = susceptible - dose dependent, ≥16 = resistant; cefotaxime: ≤1 = susceptible, 2 = intermediate, ≥4 = resistant; ceftazidime: ≤4 = susceptible, 8 = intermediate, ≥16 = resistant; ertapenem: ≤0.5 = susceptible, 1 = intermediate, ≥2 = resistant; imipenem/meropenem/doripenem: ≤1 = susceptible, 2 = intermediate, ≥4 = resistant.<sup>[19]</sup>

producers, contributing to false-negative results. The remaining antibiotics displayed a higher number of false negatives when both the CLSI<sup>[19]</sup> and EUCAST<sup>[20]</sup> MIC clinical breakpoint ranges were applied. Another study has shown ertapenem to be a good indicator for carbapenemase production, as the MICs are usually higher than those of the other carbapenems; however, they have also shown the specificity to be problematic.<sup>[17]</sup> In 2015, Maurer *et al.*<sup>[16]</sup> showed that CLSI clinical breakpoints for ertapenem and meropenem non-susceptibility displayed lower sensitivity than

the EUCAST recommendation. Nevertheless, as recommended by EUCAST and published reports, CLSI and EUCAST guideline clinical breakpoints are sufficient for making treatment decisions, while carbapenemase detection and confirmation is recommended for epidemiological and infection prevention and control purposes.<sup>[17,20]</sup> The latter can be achieved by making use of EUCAST epidemiological cut-off values, which are considerably lower than the clinical breakpoints and detect early resistance.<sup>[14]</sup> The EUCAST guidelines for detection of resistance mechanisms and specific

**Table 3. MIC breakpoint values for the cephalosporins and carbapenems and EUCAST guideline clinical breakpoint<sup>[20]</sup> interpretation**

Antimicrobial agent	MIC (mg/mL)	NDMs	OXA-48 and variants	VIMs	GESs	IMPs	KPCs	Total
Cefotaxime	≤1	7	148	2	-	-	-	209
	2	-	9	-	-	-	-	15
	4	-	16	-	1	1	-	21
	8	1	9	1	-	-	-	13
	16	4	10	-	-	-	-	23
	32	11	18	3	2	1	-	45
	>32	881	768	102	21	33	18	2 352
Ceftazidime	≤1	7	162	2	-	1	-	227
	2	-	11	-	1	-	-	17
	4	2	7	-	1	-	-	17
	8	-	19	-	1	-	-	29
	16	3	88	2	2	-	-	117
	>16	892	691	104	19	34	18	2 271
Cefepime	≤1	8	168	2	1	1	-	260
	2	2	20	1	-	-	-	32
	4	4	14	-	-	2	-	41
	8	12	21	2	2	4	-	65
	16	16	60	9	2	5	-	106
	>16	862	695	94	19	23	18	2 174
Ertapenem	≤0.5	13	128	12	3	1	-	274
	1	11	195	21	-	3	-	324
	>1	727	608	57	13	6	10	1 721
	2	-	8	4	-	7	-	39
	4	4	20	10	1	9	2	56
	>4	149	19	4	7	9	6	264
Imipenem	≤1	35	634	8	2	8	1	1 050
	≤2	40	157	14	4	20	1	429
	4	70	40	58	2	2	3	201
	8	274	45	15	2	1	5	356
	>8	485	102	13	14	4	8	642
Meropenem	≤1	34	659	27	3	27	1	1 150
	2	18	77	15	1	1	-	169
	4	49	60	21	1	2	-	216
	8	82	38	27	1	2	4	205
	>8	721	144	18	18	3	13	938
Doripenem	Not tested: not included in panel	155	52	24	9	26	8	428
	≤1	29	669	16	2	8	1	1 072
	2	28	56	14	-	-	-	155
	4	49	54	12	1	1	2	164
	>4	643	147	42	12	-	7	859

MIC = minimal inhibitory concentration; EUCAST = European Committee on Antimicrobial Susceptibility Testing; MBLs = metallo-beta-lactamases; NDMs = New Delhi MBLs; VIMs = Verona integron-encoded MBLs; GESs = Guiana extended-spectrum beta-lactamases; IMPs = imipenemases; KPCs = *Klebsiella pneumoniae* carbapenemases. The white fields indicate the susceptible MIC breakpoint values according to EUCAST breakpoints and the number of carbapenemase-producing isolates that would have been missed. EUCAST clinical breakpoints: cefepime: ≤1 = susceptible, >4 = resistant; cefotaxime: ≤1 = susceptible, >2 = resistant; ceftazidime: ≤1 = susceptible, >4 = resistant; ertapenem: ≤0.5 = susceptible, >1 = resistant; imipenem/meropenem: ≤2 = susceptible, >8 = resistant; doripenem: ≤1 = susceptible, >2 = resistant.<sup>[20]</sup>

resistances of clinical and/or epidemiological importance<sup>[14,30]</sup> state that neither ertapenem nor imipenem are ideal agents, as ertapenem has a high sensitivity and low specificity and imipenem should not be used as a stand-alone screening agent because the separation between wild-type (i.e. susceptible) organisms and carbapenemase producers is poor. Meropenem is the recommended agent because it has the best compromise between sensitivity and specificity. This recommendation was further reiterated in a 2016 study by Fattouh

*et al.*<sup>[15]</sup> investigating the meropenem MIC distribution profile of a large number of Enterobacteriaceae isolates with reduced susceptibility to carbapenems. They showed that based on CLSI and EUCAST clinical breakpoint interpretive criteria, 14% and 20% of carbapenemase producers, respectively, displayed MICs within the susceptible range, while 86% and 98.4% of carbapenemase-producing isolates were identified using the CLSI and EUCAST screening recommendations, respectively.<sup>[15]</sup> Screening recommendations are

therefore recommended as the preferred guideline for epidemiological and infection prevention and control purposes, as they detect carbapenemase producers exhibiting low MICs; this means that lower MIC dilutions would need to be included for screening, and this poses a limitation in the current study. In order for us to be able to do this, dilutions lower than the lowest MIC dilution are required for analysis, and this was not achievable using the automated MicroScan Walkaway system. Although the number of missed carbapenemase-producing isolates would have been reduced and consequently the least number of CPE isolates would be misidentified as epidemiologically susceptible, the exact numbers could therefore not be quantified. Serial broth microdilution methods are the ideal and recommended method of choice. However, this method is tedious and requires expertise, as antibiotic concentrations and dilutions need to be extremely precise and accurate. An epidemiological cut-off value for meropenem of 0.125 mg/mL as endorsed by EUCAST<sup>[14]</sup> maximises CPE detection and is therefore the recommended approach; however, this is only feasible in a region with low carbapenemase prevalence<sup>[15]</sup> and is therefore not ideal in our settings owing to the high number of OXA-48- and NDM-producing Enterobacteriaceae. Molecular methods are more accurate for the detection of carbapenemases, but they too require expertise and are expensive.<sup>[31]</sup>

EUCAST recommends that following the routine detection of reduced carbapenem susceptibility, additional phenotypic methods for the detection of carbapenemases should be applied.<sup>[14]</sup> Combination disc tests (CDTs) are discs or tablets with a carbapenem and various inhibitors. Inhibitors such as boronic acid and dipicolinic acid inhibit class A and class B carbapenemases, respectively. The AmpC beta-lactamase inhibitor cloxacillin has been included to differentiate between AmpC hyperproduction plus porin loss and carbapenemase production. As class D (OXA-48) inhibitors have not been included in phenotypic panels, resistance to piperacillin/tazobactam and high-level resistance to temocillin (MIC >128 mg/mL) can be used as phenotypic markers.<sup>[14]</sup> In a 2015 study<sup>[16]</sup> aiming to develop a diagnostic flowchart using phenotypic screening and confirmation tests for clinical laboratories, the disc diffusion method using meropenem as the antimicrobial agent of choice was favoured for screening, as automated microdilution AST methods lack sensitivity and specificity. The authors support their

findings by the fact that disc diffusion is cheap and simple to perform and can be implemented by many laboratories for routine AST. For confirmation of carbapenemases, Maurer *et al.*<sup>[16]</sup> explored several options for the various carbapenemases and conclusively decided that a combination of the EUCAST meropenem screening cut-off of <28 mm or MIC >0.125 mg/mL<sup>[14]</sup> and ertapenem (or meropenem) aminophenyl boronic acid and EDTA CDTs plus temocillin disc diffusion (or gradient diffusion-based MIC determination) on Mueller-Hinton agar containing cloxacillin

showed promise. Considering these published recommendations and the South African Society for Clinical Microbiology's current recommendation of a shift towards implementing the use of EUCAST guidelines in our SA setting, we have adapted the proposed diagnostic flowchart from Maurer *et al.*<sup>[16]</sup> and the EUCAST recommendations using EUCAST guidelines<sup>[14]</sup> for use in routine, academic, reference and national reference laboratories (Fig. 2). This would assist in the identification and detection of CPE for both clinical management and infection prevention and control purposes.




Fig. 2. Diagnostic flow chart for detection of carbapenemases in Enterobacteriaceae, adapted from Maurer *et al.*<sup>[16]</sup> and the European Committee on Antimicrobial Susceptibility Testing<sup>[14]</sup> recommendations. Level I indicates processes to be performed at routine laboratories, level II indicates processes to be performed at academic and reference laboratories, and level III indicates processes to be performed at the national reference laboratory. (MIC = minimal inhibitory concentration; CDT = combined disc test; APBA = aminophenyl boronic acid; MH = Mueller-Hinton agar; MH-CLX = Mueller-Hinton agar containing cloxacillin; EDTA = ethylenediaminetetra-acetic acid. \*Note: meropenem is known to have a lower sensitivity.)

## Conclusions

We have shown an increase in carbapenemase-producing Enterobacteriaceae over the study period. While phenotypic methods are acceptable for routine diagnosis, clinicians should be aware that carbapenemase-producing isolates are being misidentified as carbapenem-susceptible owing to limitations in routine phenotypic methodology. The application of CLSI and EUCAST clinical breakpoints, although suitable for clinical management, is not ideal for public health and infection prevention and control purposes; the use of epidemiological cut-off values is more appropriate for the latter. However, this is only fitting for use in a region with low CPE prevalence. A comprehensive CPE phenotypic screening method should be implemented to streamline isolates for molecular testing, which is relatively expensive.

**Acknowledgements.** We thank Ruth Mohlabeng, Wilhelmina Strasheim, Cheryl Hamman, Rubeina Badat, Gloria Molaba, Naseema Bulbulia and Rosah Mabokachaba for assistance with the laboratory work and Boniwe Makwakwa and Penny Crowther-Gibson for assistance with the database. Many thanks to the Centre for Healthcare-associated infections, Antimicrobial Resistance and Mycoses writing group, and particularly Dr Husna Ismail for review of the manuscript.

**Author contributions.** AS-M conceived and designed the experiments, performed the experiments, analysed the data and wrote the manuscript. OP was instrumental in the study design and its co-ordination and in editing of the manuscript. Both authors read and approved the final manuscript.

**Funding.** This work was funded by the National Institute for Communicable Diseases. No external funding was obtained.

**Conflicts of interest.** None.

- Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: Epidemiology and prevention. *Clin Infect Dis* 2011;53(1):60-67. <https://doi.org/10.1093/cid/cir202>
- Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections: A call to action for the medical community from the Infectious Diseases Society of America. *Clin Infect Dis* 2008;46(2):155-164. <https://doi.org/10.1086/524891>
- Kocsis B, Szabó D. Antibiotic resistance mechanisms in Enterobacteriaceae. In: Méndez-Vilas A, ed. *Microbial Pathogens and Strategies for Combating Them: Science, Technology and Education*, Vol. 1. Badajoz, Spain: Formatex Research Center, 2013.
- Livermore DM. My CRE is a CPO, is yours? *Public Health England, Antimicrobial Resistance and Healthcare Associated Infections Reference Unit (AMRHAI) News*, Summer 2013. Issue 03.2. PHE publications gateway number: 2013137. <http://webarchive.nationalarchives.gov.uk/20140505163041/http://www.hpa.org.uk/ProductsServices/MicrobiologyPathology/LaboratoriesAndReferenceFacilities/AntimicrobialResistanceAndHealthcareAssociatedInfections/ARMRLNewsletters/> (accessed 5 May 2018).
- Livermore DM, Woodford N. The beta-lactamase threat in Enterobacteriaceae, *Pseudomonas* and *Acinetobacter*. *Trends Microbiol* 2006;14(9):413-420. <https://doi.org/10.1016/j.tim.2006.07.008>
- Brink A, Coetzee J, Clay C, et al. The spread of carbapenem-resistant Enterobacteriaceae in South Africa: Risk factors for acquisition and prevention. *S Afr Med J* 2012;102(7):599-601.
- Sekyere JO, Govinden U, Essak S. The molecular epidemiology and genetic environment of carbapenemases detected in Africa. *Microb Drug Resist* 2015;22(1):59-68. <https://doi.org/10.1089/mdr.2015.0053>
- Rodríguez-Martínez JM, Cano ME, Velasco C, Martínez-Martínez L, Pascual A. Plasmid-mediated quinolone resistance: An update. *J Infect Chemother* 2011;17(2):149-182. <https://doi.org/10.1007/s10156-010-0120-2>

- Rodríguez-Martínez JM, Nordmann P, Fortineau N, Poirel L. VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from *Escherichia coli* and *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2010;54(1):471-476. <https://doi.org/10.1128/AAC.00458-09>
- Fernández-Cuenca F, Rodríguez-Martínez JM, Gómez-Sánchez MA, de Alba PD, Infante-Martínez V, Pascual A. Production of a plasmid-encoded OXA-72 beta-lactamase associated with resistance to carbapenems in a clinical isolate *Acinetobacter junii*. *Int J Antimicrob Agents* 2012;39(1):93-94. <https://doi.org/10.1016/j.ijantimicag.2011.07.017>
- Che A, Bulens SN, Kongphet-Tran T, et al. Improved phenotype-based definition for identifying carbapenemase producers among carbapenem-resistant Enterobacteriaceae. *Emerg Infect Dis* 2015;21(9):1611-1616. <https://doi.org/10.3201/eid2109.150198>
- Hayakawa K, Miyoshi-Akiyama T, Kirikae T, et al. Molecular and epidemiological characterization of IMP-type metallo-beta-lactamase-producing *Enterobacter cloacae* in a large tertiary care hospital in Japan. *Antimicrob Agents Chemother* 2014;58(6):3441-3450. <https://doi.org/10.1128/AAC.02652-13>
- Singh-Moodley A, Ekermans P, Perovic O. Emerging carbapenem-resistant *Enterobacter cloacae* producing OXA-48-, VIM- and IMP-type-beta-lactamases in Eastern Cape hospitals in South Africa. *Open J Med Microbiol* 2015;5(4):246-253. <https://doi.org/10.4236/ojmm.2015.54030>
- European Committee on Antimicrobial Susceptibility Testing (EUCAST). EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. 2017. [http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\\_files/Resistance\\_mechanisms/EUCAST\\_detection\\_of\\_resistance\\_mechanisms\\_170711.pdf](http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_170711.pdf) (accessed 5 May 2018).
- Fattouh R, Tijet N, McGeer A, Poutanen SM, Melano RG, Patel SN. What is the appropriate meropenem MIC for screening of carbapenemase-producing Enterobacteriaceae in low-prevalence settings? *Antimicrob Agents Chemother* 2016;60(3):1556-1559. <https://doi.org/10.1128/AAC.02304-15>
- Maurer FP, Castelberg C, Quiblier C, Bloemberg GV, Hombach M. Evaluation of carbapenemase screening and confirmation tests with Enterobacteriaceae and development of a practical diagnostic algorithm. *J Clin Microbiol* 2015;53(1):95-104. <https://doi.org/10.1128/JCM.01692-14>
- Nordmann P, Gniadkowski M, Giske CG, et al. Identification and screening of carbapenemase-producing Enterobacteriaceae. *Clin Microbiol Infect* 2012;18(5):432-438.
- Richter SS, Marchaim D. Screening for carbapenem-resistant Enterobacteriaceae: Who, when and how? *Virulence* 2017;8(4):417-426. <https://doi.org/10.1080/21505594.2016.1255381>
- Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: Twenty seventh informational supplement. 2017. Wayne, Penn., USA: CLSI, 2017.
- European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 7.1, 2017. [http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\\_files/Breakpoint\\_tables/v\\_7.1\\_Breakpoint\\_Tables.pdf](http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_7.1_Breakpoint_Tables.pdf) (accessed 5 May 2018).
- Brink AJ, Coetzee J, Clay CG, et al. Emergence of New Delhi metallo-beta-lactamase (NDM-1) and *Klebsiella pneumoniae* carbapenemase (KPC-2) in South Africa. *J Clin Microbiol* 2011;50(2):525-527. <https://doi.org/10.1128/JCM.05956-11>
- Brink AJ, Coetzee J, Corcoran C, et al. Emergence of OXA-48 and OXA-181 carbapenemases among Enterobacteriaceae in South Africa and evidence of *in vivo* selection of colistin resistance as a consequence of selective decontamination of the gastrointestinal tract. *J Clin Microbiol* 2013;51(1):369-372. <https://doi.org/10.1128/JCM.02234-12>
- Govind C, Moodley K, Peer AK, et al. NDM-1 imported from India – first reported case in South Africa. *S Afr Med J* 2013;103(7):476-478. <https://doi.org/10.7196/SAMJ.6593>
- Jacobson RK, Manesen MR, Moodley C, et al. Molecular characterisation and epidemiological investigation of an outbreak of bla<sub>OXA-181</sub> carbapenemase-producing isolates of *Klebsiella pneumoniae* in South Africa. *S Afr Med J* 2015;105(12):1030-1035. <https://doi.org/10.7196/SAMJ.2015.v105i12.9926>
- Lowman W, Sriruttan C, Nana T, et al. NDM-1 has arrived: First report of carbapenem resistance mechanism in South Africa. *S Afr Med J* 2011;101(12):873-875.
- Mimoz O, Gregoire N, Poirel L, Marliat M, Couet W, Nordmann P. Broad-spectrum beta-lactam antibiotics for treating experimental peritonitis in mice due to *Klebsiella pneumoniae* producing the carbapenemase OXA-48. *Antimicrob Agents Chemother* 2012;56(5):2759-2760. <https://doi.org/10.1128/AAC.06069-11>
- Glupczynski Y, Huang TD, Bouchahrouf W, et al. Rapid emergence and spread of OXA-48-producing carbapenem-resistant Enterobacteriaceae isolates in Belgian hospitals. *Int J Antimicrob Agents* 2012;39(2):168-172. <https://doi.org/10.1016/j.ijantimicag.2011.10.005>
- Girlich D, Poirel L, Nordmann P. Value of the modified Hodge test for detection of emerging carbapenemases in Enterobacteriaceae. *J Clin Microbiol* 2012;50(2):477-479. <https://doi.org/10.1128/JCM.05247-11>
- Singh-Moodley A, Perovic O. Antimicrobial susceptibility testing in predicting the presence of carbapenemase genes in Enterobacteriaceae in South Africa. *BMC Infect Dis* 2016;16(536). <https://doi.org/10.1186/s12879-016-1858-7>
- European Committee on Antimicrobial Susceptibility Testing (EUCAST). EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. 2013. [http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\\_files/Resistance\\_mechanisms/EUCAST\\_detection\\_of\\_resistance\\_mechanisms\\_v1.0\\_20131211.pdf](http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_v1.0_20131211.pdf) (accessed: 5 May 2018).
- Lutgring JD, Limbago BM. The problem of carbapenemase-producing-carbapenem-resistant Enterobacteriaceae detection. *J Clin Microbiol* 2016;54(3):529-534. <https://doi.org/10.1128/JCM.02771-15>

Accepted 6 November 2017.